lundi 19 novembre 2018

Onco Actu du 19 novembre 2018

2. Etiologie

Science Surgery: ‘Why do never-smokers get lung cancer?’ [Cancer Research UK]

3.1.1 Prévention - Tabac - e-cigs

She Couldn’t Quit Smoking. Then She Tried Juul. [NY Times]

4.2 Dép., diag. & prono. - Génome

These DNA Startups Want to Put Your Whole Genome on the Blockchain [Wired]

5.1 Traitements - Pré-clinique

PI3K Inhibitors: You’re Doing It Wrong [In the Pipeline]

5.10 Traitements - Essais

Standard chemo still most effective for throat cancers caused by HPV [Cancer Research UK]

Patients with HPV-positive throat cancer should keep taking chemotherapy [Institute of Cancer Research]

5.12 Immunothérapies

New dual-action cancer-killing virus [MRC]

5.12.4 Immunothérapies - Essais

AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC [FierceBiotech]

MYSTIC deals another blow to AstraZeneca as Imfinzi misses on OS [BiopharmaDive]

5.12.6 Immunothérapies - AMM

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018 [EMA]

5.12.8 Immunothérapies - Economie

Innovative skin cancer drug available on Cancer Drugs Fund [NICE]

5.2 Pharma

Belgium’s Camel-IDS reels in €37M to push breast cancer radiotherapy [FierceBiotech]

With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A funding [EndPoints]

5.2.1 Pharma - Partenariats

After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer [FiercePharma]

5.2.3 Pharma - économie

Pfizer preps a laundry list of drug price hikes for the New Year — let the political fireworks begin [EndPoints]

Pfizer to raise U.S. drug prices in January after previously backing down [Reuters]

5.3 Traitements - FDA, EMA, NICE...

Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs [FDA]

5.3.4 Traitements - AMM (FDA, EMA,...)

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia [Amgen]

Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer [Novartis]

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease [Janssen]

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot [FDA]

EMA Recommends Granting a Marketing Authorisation for Apalutamide [ESMO]

5.9.4 ENA

Agendia Breast Cancer Tests Show Promise for Improved Therapy Prediction [Genome Web]

6.11 Patients

Tackling Cancer Anxiety [NY Times]